Search Browse Earnings

REGENXBIO Inc.

Nasdaq:RGNX

Biological Products, (No Diagnostic Substances)·ROCKVILLE, MD

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

REGENXBIO Inc. — SlamSEC

Revenue

$83.3M

-26.1% YoY

FY 2025

Adj. EBITDA

-$217.1M

-260.6% margin

FY 2025

Net Income

-$227.1M

-272.5% margin

FY 2025

EPS (Diluted)

-$4.59

FY 2025

Stock Price

$8.65

-0.7%

2026-03-06

52W Range

$5.04 – $16.19

P/E Ratio

-1.9x

Market Cap

$446.5M

Cash

$57.5M

FY 2025

Total Debt

—

Net Cash

$57.5M

FY 2025

Enterprise Value

$388.9M

Debt / EBITDA

0.3x

FY 2025

EV / EBITDA

-1.8x

Employees

—